M&A Deal Summary

Secura Bio Acquires Verastem - COPIKTRA

On September 30, 2020, Secura Bio acquired life science company Verastem - COPIKTRA from Verastem for 381M USD

Acquisition Highlights
  • This is Secura Bio’s 2nd transaction in the Life Science sector.
  • This is Secura Bio’s largest (disclosed) transaction.
  • This is Secura Bio’s 1st transaction in the United States.
  • This is Secura Bio’s 1st transaction in Massachusetts.

M&A Deal Summary
Date 2020-09-30
Target Verastem - COPIKTRA
Sector Life Science
Buyer(s) Secura Bio
Sellers(s) Verastem
Deal Type Divestiture
Deal Value 381M USD

Target

Verastem - COPIKTRA

Needham, Massachusetts, United States
Verastem's COPIKTRA (duvelisib) is an oral inhibitor of phosphoinositide 3-kinase (PI3K), and the first FDA-approved dual inhibitor of PI3K-delta and PI3K-gamma.

Search 200,197 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Secura Bio

Las Vegas, Nevada, United States
Category Company
Sector Life Science
DESCRIPTION

Secura Bio is a commercial-stage biopharmaceutical company that offers oncology therapies for physicians and their patients. Secura Bio is based in Las Vegas, Nevada.

DEAL STATS #
Overall 2 of 2
Sector (Life Science) 2 of 2
Type (Divestiture) 2 of 2
State (Massachusetts) 1 of 1
Country (United States) 1 of 1
Year (2020) 1 of 1
Size (of disclosed) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2019-03-12 Novartis AG - Farydak

Basel, Switzerland

Farydak is a histone deacetylase (HDAC) inhibitor that inhibits the enzymatic activity of HDACs at nanomolar concentrations. HDACs catalyze the removal of acetyl groups from the lysine residues of histones and some non-histone proteins. Inhibition of HDAC activity results in increased acetylation of histone proteins, an epigenetic alteration that results in a relaxing of chromatin, leading to transcriptional activation.

Buy -

Seller(S) 1

SELLER

Verastem

Needham, Massachusetts, United States
Category Company
Founded 2010
Sector Life Science
Employees73
Revenue 3M USD (2022)
DESCRIPTION

Verastem is a development-stage biopharmaceutical company committed to the development and commercialization of new medicines to improve the lives of patients diagnosed with cancer. Verastem was founded in 2010 and is based in Needham, Massachusetts.

DEAL STATS #
Overall 1 of 1
Sector (Life Science) 1 of 1
Type (Divestiture) 1 of 1
State (Massachusetts) 1 of 1
Country (United States) 1 of 1
Year (2020) 1 of 1
Size (of disclosed) 1 of 1
Mergr

Product

Company

Legal